We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RVNC market cap is 428.24M. The company's latest EPS is USD -3.1019 and P/E is -1.29.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 49.33M | 58.13M | 56.78M | 69.8M | 51.94M |
| Operating Income | -58.03M | -65.5M | -139.29M | -53.95M | -46.83M |
| Net Income | -59.79M | -67.32M | -141.18M | -55.7M | -53.15M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 413k | 15.33M | 77.8M | 132.57M | 234.04M |
| Operating Income | -164.46M | -273.16M | -274.68M | -341.96M | -316.78M |
| Net Income | -159.43M | -282.09M | -281.31M | -356.42M | -323.99M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 547.8M | 597.54M | 532.49M | 478.45M | 508.12M |
| Total Liabilities | 574.47M | 570.75M | 638.69M | 630.06M | 606.79M |
| Total Equity | -26.67M | 26.79M | -106.2M | -151.6M | -98.67M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 340.29M | 720.22M | 531.16M | 581.9M | 478.45M |
| Total Liabilities | 114.8M | 345.93M | 462.69M | 569.3M | 630.06M |
| Total Equity | 225.49M | 374.29M | 68.47M | 12.6M | -151.6M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -69.5M | -122.88M | -173.84M | -216.58M | -65.94M |
| Investing | 95.32M | 55.78M | 107.37M | 109.74M | -31.71M |
| Financing | 3.27M | 100.74M | 138.2M | 136.57M | 92.83M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -106.16M | -178.5M | -221.54M | -193.55M | -216.58M |
| Investing | -17.59M | 12.13M | -29.67M | -138.8M | 109.74M |
| Financing | 221.66M | 331.48M | 29.87M | 331.69M | 136.57M |
| Market Cap | 428.24M |
| Price to Earnings Ratio | -1.29 |
| Price to Sales Ratio | 1.79 |
| Price to Cash Ratio | 3.04 |
| Price to Book Ratio | -2.76 |
| Dividend Yield | - |
| Shares Outstanding | 104.45M |
| Average Volume (1 week) | 2.17M |
| Average Volume (1 Month) | 1.99M |
| 52 Week Change | -82.30% |
| 52 Week High | 24.87 |
| 52 Week Low | 2.30 |
| Spread (Intraday) | 0.23 (5.44%) |
| Company Name | Revance Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.revance.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
